Stryker Corporation $SYK Shares Acquired by Sigma Investment Counselors Inc.

Sigma Investment Counselors Inc. raised its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 41,021 shares of the medical technology company’s stock after buying an additional 521 shares during the quarter. Stryker accounts for approximately 0.9% of Sigma Investment Counselors Inc.’s investment portfolio, making the stock its 28th biggest holding. Sigma Investment Counselors Inc.’s holdings in Stryker were worth $16,229,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Mar Vista Investment Partners LLC boosted its position in shares of Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after purchasing an additional 8,353 shares during the period. United Services Automobile Association acquired a new stake in shares of Stryker in the 1st quarter valued at about $2,857,000. AXS Investments LLC boosted its position in shares of Stryker by 13.7% in the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after purchasing an additional 1,062 shares during the period. Park Edge Advisors LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at about $679,000. Finally, Hendley & Co. Inc. boosted its position in shares of Stryker by 60.3% in the 2nd quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after purchasing an additional 5,274 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Truist Financial decreased their target price on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research report on Wednesday. Rothschild & Co Redburn assumed coverage on Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Rothschild Redb raised Stryker to a “hold” rating in a research report on Thursday, September 18th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $431.76.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

Stryker stock opened at $374.67 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business has a 50 day simple moving average of $379.40 and a 200-day simple moving average of $378.77. The stock has a market capitalization of $143.24 billion, a PE ratio of 49.63, a price-to-earnings-growth ratio of 2.70 and a beta of 0.94. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period last year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.